Meta-analysis: Second generation antidepressants and headache.

  title={Meta-analysis: Second generation antidepressants and headache.},
  author={Shilpa Telang and Celeste Walton and Baris Olten and Michael H. Bloch},
  journal={Journal of affective disorders},
Psychopharmacology of headache and its psychiatric comorbidities.
Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
It is suggested that patients with early non-improvement in insomnia and anxiety were not suitable for switches in SSRI monotherapy, and patients with treatment-emergent symptoms, especially headaches and tremors, wereNot suitable for switching from monotherapy to another SSRI.
Effects of mindfulness-based intervention programs on sleep among people with common mental disorders: A systematic review and meta-analysis
All MBI programs (MBTT, MBCT, IMMI and MBSR), except MM, are effective options to improve sleep problems among people with depression or anxiety disorder.
A randomized controlled trial on the comparative effectiveness of mindfulness-based cognitive therapy and health qigong-based cognitive therapy among Chinese people with depression and anxiety disorders
Individual growth curve models indicated that alterations in perceived stress was the common predictor of mood changes in both intervention groups, and the predominant emphasis on physical health in health qigong-based cognitive therapy makes it more acceptable and effective than mindfulness-based Cognitive Therapy as applied in Chinese individuals with mood disorders.
New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
This article aims to review the commonly prescribed serotonin-norepinephrine reuptake inhibitors and the current clinical evidence regarding their considerations in perioperative anesthesia and analgesia.


Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder
Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Evaluating the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder found it efficacious, safe, and well tolerated in the treatment of panic disorder.
A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder
St John's wort was significantly more effective than fluoxetine and showed a trend toward superiority over placebo and appeared to be safe and well tolerated.
Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
Results support the safety and efficacy of sertraline for the short-term treatment of patients with panic disorder.
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
A large and significant treatment effect on the Montgomery-Asberg Depression Rating Scale and statistically significant improvement on the CGI-S demonstrated meaningful depressive symptom improvements.
Paroxetine versus placebo: a double-blind comparison in depressed patients.
Paroxetine was an effective, well tolerated, and safe antidepressant in depressed outpatients and side effects were typical of the SSRI class of drugs.
The Treatment of Migraine Headache in the Presence of Selective Serotonin Reuptake Inhibitor Use: Pharmacokinetic Considerations
  • A. Macca
  • Medicine, Psychology
    The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • 2015
The common diagnosis of depression/anxiety and migraine headache and the first-line pharmacological treatments that accompany these diseases are reviewed and serious interactions that can arise from certain drug combinations including serotonin syndrome are discussed.
Treatment of Post-Myocardial Infarction Depressive Disorder: A Randomized, Placebo-Controlled Trial With Mirtazapine
This trial shows efficacy of mirtazapine on primary and secondary depression measures and seems to be safe in the treatment of post-MI depression.